Kirsten rat sarcoma virus proto-oncogene G13D mutant neoantigen (KRAS G13D neoantigen)

KRAS G13D mutant neoantigens are tumor-specific peptides derived from the KRAS protein with a glycine-to-aspartic acid substitution at position 13. These peptides are processed and presented on the surface of cancer cells by Human Leukocyte Antigen (HLA) molecules, making them targets for the adaptive immune system. Unlike wild-type KRAS, these neoantigens are not expressed in normal tissues, providing a high degree of tumor specificity for immunotherapies. Therapeutic strategies include cancer vaccines (mRNA or peptide-based) and adoptive T-cell therapies (TCR-T) designed to recognize the specific peptide-HLA complex. The G13D mutation is particularly prevalent in colorectal cancer and is associated with distinct signaling properties compared to G12 mutations.

Other names

KRAS G13DKRAS p.G13D neoantigenKRAS codon 13 mutation neoantigenMutant KRAS G13D peptide-HLA complex

Induction of a T-cell mediated immune response specifically against cancer cells presenting the KRAS G13D mutant peptide on HLA molecules, leading to targeted tumor cell lysis.